Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report First Quarter 2020 Financial Results
April 22, 2020 07:30 ET | Repligen Corporation
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020....
Rohin
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
February 27, 2020 07:30 ET | Repligen Corporation
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results
February 20, 2020 07:30 ET | Repligen Corporation
Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Fourth Quarter and Full Year 2019 Financial Results
February 06, 2020 07:30 ET | Repligen Corporation
WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday,...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 07:30 ET | Repligen Corporation
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
October 31, 2019 07:30 ET | Repligen Corporation
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32%...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Third Quarter 2019 Financial Results
October 23, 2019 10:29 ET | Repligen Corporation
WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31,...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
August 01, 2019 07:30 ET | Repligen Corporation
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growthRaises revenue guidance to $264-$268 million for full year 2019, representing 29%-31%...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Second Quarter 2019 Financial Results
July 23, 2019 16:01 ET | Repligen Corporation
WALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1,...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
July 19, 2019 19:42 ET | Repligen Corporation
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of...